Dedicator of cytokinesis 8 (DOCK8) deficiency

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 6, 2010, Pages 515-520

  Su, Helen C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

combined immunodeficiency; DOCK8; hyper IgE; lymphopenia; viral susceptibility

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIGEN; ANTIINFECTIVE AGENT; BLEACHING AGENT; CIDOFOVIR; CORTICOSTEROID; IMIQUIMOD; IMMUNOGLOBULIN; TOPICAL ANTIINFECTIVE AGENT; VALACICLOVIR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; CELL EXPANSION; COMBINED IMMUNODEFICIENCY; CORTICOSTEROID THERAPY; DEDICATOR OF CYTOKINESIS 8 DEFICIENCY; DOCK8 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GENITAL HERPES; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HYPER IGE SYNDROME; IN VITRO STUDY; INFECTION CONTROL; INFECTION SENSITIVITY; LUNG INFECTION; LYMPHOCYTOPENIA; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SKIN INFECTION; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERRUCA VULGARIS; VIRUS INFECTION;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNITY, HUMORAL; INFECTION; JOB'S SYNDROME; LYMPHOPENIA; MICE; MUTATION; T-LYMPHOCYTES;

EID: 78449249501     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833fd718     Document Type: Review

References (41)

1. Woellner C, Gertz EM, Schaffer AA, et al. Mutations in STAT3 and diagnostic guidelinesforhyper-IgEsyndrome. J Allergy Clin Immunol 2010; 125:424-432.
2. Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol 2009; 21:487-492.
3. Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am 2008 28:277-291; viii.
4. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058-1062.
5. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608-1619.
6. Renner ED, Puck JM, Holland SM, et al. Autosomal recessive hyperimmuno-globulin E syndrome: a distinct disease entity. J Pediatr 2004; 144:93-99.
7. Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25:745-755.
8. Woellner C, Schaffer AA, Puck JM, et al. The hyper IgE syndrome and mutations in TYK2. Immunity 2007; 26:535; author reply 536.
9. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu Rev Med 2010; 61:437-455.
10. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361:2046-2055.
11. Engelhardt KR, McGhee S, Winkler S, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:1289.e1284-1302.e1284.
12. Gatz SA, Benninghoff U, Schutz C, et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant 2010 Jul 12. [Epub ahead of print].
13. Ruusala A, Aspenstrom P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett 2004; 572:159-166.
14. Hijikata A, Kitamura H, Kimura Y, et al. Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells. Bioinformatics 2007; 23:2934-2941.
15. Cote JF, Vuori K. GEF what? Dock180 and related proteins help Rac to polarize cells in new ways. Trends Cell Biol 2007; 17:383-393.
16. Meller N, Merlot S, Guda C. CZH proteins: a newfamily of Rho-GEFs. J Cell Sci 2005; 118:4937-4946.
17. Yang J, Zhang Z, Roe SM, et al. Activation of Rho GTPases by DOCK exchange factors is mediated by a nucleotide sensor. Science 2009; 325:1398-1402.
18. Fukui Y, Hashimoto O, Sanui T, et al. Haematopoieticcell- specificCDMfamily protein DOCK2 is essential for lymphocyte migration. Nature 2001; 412:826-831.
19. Nombela-Arrieta C, Lacalle RA, Montoya MC, et al. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lympho-cyte homing. Immunity 2004; 21:429-441.
20. Nombela-Arrieta C, Mempel TR, Soriano SF, et al. A central role for DOCK2 during interstitial lymphocytemotilityand sphingosine-1-phosphate-mediated egress. J Exp Med 2007; 204:497-510.
21. Sanui T, Inayoshi A, Noda M, et al. DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-theta and LFA-1, in T cells. Immunity 2003; 19:119-129.
22. Tanaka Y, Hamano S, Gotoh K, et al. T helper type 2 differentiation and intracellulartrafficking of the interleukin 4 receptor-alphasubunitcontrolled by the Rac activator Dock2. Nat Immunol 2007; 8:1067-1075.
23. Nishikimi A, Fukuhara H, Su W, et al. Sequential regulation of DOCK2 dynamics by two phospholipids during neutrophil chemotaxis. Science 2009; 324:384-387.
24. Kunisaki Y, Nishikimi A, Tanaka Y, et al. DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis. J Cell Biol 2006; 174:647-652.
25. Gotoh K, Tanaka Y, Nishikimi A, et al. Differential requirement for DOCK2 in migration of plasmacytoid dendriticcellsversus myeloid dendritic cells. Blood 2008; 111:2973-2976.
26. Gotoh K, Tanaka Y, Nishikimi A, et al. Selective control of type I IFN induction bythe Racactivator DOCK2 during TLR-mediated plasmacytoid dendriticcell activation. J Exp Med 2010; 207:721-730.
27. Yelo E, Bernardo MV, Gimeno L, et al. Dock10, a novel CZH protein selectively induced by interleukin-4 in human B lymphocytes. Mol Immunol 2008; 45:3411-3418.
28. Nishikimi A, Meller N, Uekawa N, et al. Zizimin2: a novel, DOCK180-related Cdc42 guanine nucleotide exchange factor expressed predominantly in lymphocytes. FEBS Lett 2005; 579:1039-1046.
29. Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054-1062; quiz 1063-1054.
30. Lei JY, Wang Y, Jaffe ES, et al. Microcysticadnexal carcinomaassociatedwith primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am J Dermatopathol 2000; 22:524-529.
31. Griggs BL, Ladd S, Saul RA, et al. Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities. Geno-mics 2008; 91:195-202.
32. Vinci G, Chantot-Bastaraud S, El Houate B, et al. Association of deletion 9p, 46,XY gonadal dysgenesis and autistic spectrum disorder. Mol Hum Reprod 2007; 13:685-689.
33. Miyamoto Y, Yamauchi J. Cellular signaling of Dockfamily proteins in neural function. Cell Signal 2010; 22:175-182.
34. Randall KL, Lambe T, Johnson A, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol 2009; 10:1283-1291.
35. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776.
36. Al Khatib S, Keles S, Garcia-Lloret M, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol 2009; 124:342-348; 348.e341-348.e345.
37. Kang JU, Koo SH, Kwon KC, Park JW. Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int J Oncol 2010; 37:327-335.
38. Takahashi K, Kohno T, Ajima R, et al. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int J Oncol 2006; 28:321-328.
39. Idbaih A, Carvalho Silva R, Criniere E, et al. Genomic changes in progression of low-grade gliomas. J Neurooncol 2008; 90:133-140.
40. Heidenblad M, Schoenmakers EF, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 2004; 64:3052-3059.
41. Takada H, Imoto I, Tsuda H, et al. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 2006; 25:6554-6562.